

**Cancer drug costs for a month of treatment at initial Food and Drug Administration approval**

<b>Generic name</b>	<b>Brand name(s)</b>	<b>Year of FDA approval</b>	<b>Monthly Cost (actual \$'s)</b>	<b>Monthly cost (2014 \$'s)</b>
vinblastine	Velban	1965	\$78	\$585
thioguanine, 6-TG	Thioguanine Tabloid	1966	\$17	\$124
hydroxyurea	Hydrea	1967	\$14	\$99
cytarabine	Cytosar-U, Tarabine PFS	1969	\$13	\$84
procarbazine	Matulane	1969	\$2	\$13
testolactone	Teslac	1969	\$179	\$1,156
mitotane	Lysodren	1970	\$134	\$814
plicamycin	Mithracin	1970	\$50	\$305
mitomycin C	Mutamycin	1974	\$5	\$23
dacarbazine	DTIC-Dome	1975	\$29	\$127
lomustine	CeeNU	1976	\$10	\$42
carmustine	BiCNU, BCNU	1977	\$33	\$129
tamoxifen citrate	Nolvadex	1977	\$44	\$170
cisplatin	Platinol	1978	\$125	\$453
estramustine	Emcyt	1981	\$420	\$1,092
streptozocin	Zanosar	1982	\$61	\$149
etoposide, VP-16	Vepesid	1983	\$181	\$430
interferon alfa 2a	Roferon A	1986	\$742	\$1,601
daunorubicin, daunomycin	Cerubidine	1987	\$533	\$1,109
doxorubicin	Adriamycin	1987	\$521	\$1,084
mitoxantrone	Novantrone	1987	\$477	\$993
ifosfamide	IFEX	1988	\$1,667	\$3,331
flutamide	Eulexin	1989	\$213	\$406
altretamine	Hexalen	1990	\$341	\$617
idarubicin	Idamycin	1990	\$227	\$411
levamisole	Ergamisol	1990	\$105	\$190
carboplatin	Paraplatin	1991	\$860	\$1,493
fludarabine phosphate	Fludara	1991	\$662	\$1,149
pamidronate	Aredia	1991	\$507	\$880
pentostatin	Nipent	1991	\$1,767	\$3,067
aldesleukin	Proleukin	1992	\$13,503	\$22,750
melphalan	Alkeran	1992	\$35	\$59
cladribine	Leustatin, 2-CdA	1993	\$764	\$1,250
asparaginase	Elspar	1994	\$694	\$1,107
paclitaxel	Taxol	1994	\$2,614	\$4,169
pegaspargase	Oncaspar	1994	\$3,006	\$4,795
vinorelbine	Navelbine	1994	\$1,035	\$1,651
anastrozole	Arimidex	1995	\$189	\$293
bicalutamide	Casodex	1995	\$311	\$482
doxorubicin liposomal	Doxil, Dox-SL, Evacet, LipoDox	1995	\$1,488	\$2,308
goserelin acetate	Zoladex	1995	\$415	\$644
porfimer sodium	Photofrin	1995	\$520	\$807

tretinoin, ATRA	Vesanoid	1995	\$2,435	\$3,777
bleomycin	Blenoxane	1996	\$421	\$634
daunorubicin liposomal	DanuoXome	1996	\$847	\$1,276
etoposide phosphate	Etopophos	1996	\$685	\$1,032
gemcitabine	Gemzar	1996	\$2,129	\$3,208
irinotecan	Camptosar	1996	\$5,326	\$8,024
nilutamide	Nilandron	1996	\$320	\$483
topotecan	Hycamtin	1996	\$2,344	\$3,531
docetaxel	Taxotere	1996	\$2,610	\$3,932
letrozole	Femara	1997	\$180	\$265
rituximab	Rituxan	1997	\$3,475	\$5,118
toremifene	Fareston	1997	\$93	\$138
BCG Live	TICE BCG	1998	\$53	\$77
capecitabine	Xeloda	1998	\$1,045	\$1,515
leuprolide acetate	Eligard, Lupron, Lupron Depot	1998	\$206	\$298
trastuzumab	Herceptin	1998	\$3,208	\$4,652
valrubicin	Valstar	1998	\$3,209	\$4,654
bexarotene	Targretin	1999	\$2,361	\$3,351
busulfan	Busulfex (Myleran)	1999	\$1,427	\$2,025
cytarabine liposomal	DepoCyt, DepoFoam	1999	\$3,351	\$4,755
denileukin	Ontak	1999	\$14,291	\$20,277
epirubicin	Ellence	1999	\$2,295	\$3,256
exemestane	Aromasin	1999	\$205	\$291
methoxsalen	Uvadex	1999	\$80	\$113
temozolomide	Temodar	1999	\$1,574	\$2,233
arsenic trioxide	Trisenox	2000	\$5,400	\$7,413
gemtuzumab ozogamicin	Mylotarg	2000	\$4,262	\$5,851
triptorelin pamoate	Trelstar Depot	2000	\$450	\$617
alemtuzumab	Campath	2001	\$19,925	\$26,595
imatinib mesylate	Gleevec	2001	\$3,401	\$4,540
fulvestrant	Faslodex	2002	\$948	\$1,246
ibrutinomab tiuxetan	Zevalin	2002	\$1,000	\$1,313
oxaliplatin	Eloxatin	2002	\$5,911	\$7,767
zoledronic acid	Zometa	2002	\$881	\$1,157
abarelix	Plenaxis depot	2003	\$2,607	\$3,350
bortezomib	Velcade	2003	\$3,392	\$4,358
gefitinib	Iressa	2003	\$1,608	\$2,066
tositumomab	Bexxar	2003	\$1,449	\$1,862
azacitidine	Vidaza, Mylosar	2004	\$3,909	\$4,892
bevacizumab	Avastin	2004	\$4,429	\$5,542
cetuximab	Erbix	2004	\$9,465	\$11,844
erlotinib	Tarceva	2004	\$4,174	\$5,223
pemetrexed disodium	Alimta	2004	\$5,086	\$6,364
lenalidomide	Revlimid	2005	\$7,989	\$9,670
nelarabine	Arranon	2005	\$19,425	\$23,511
paclitaxel albumin-stabilized nanoparticle formulation	Abraxane, Nanoparticle Paclitaxel	2005	\$5,640	\$6,826

sorafenib	Nexavar	2005	\$5,097	\$6,169
dasatinib	Sprycel	2006	\$4,529	\$5,310
decitabine	Dacogen	2006	\$4,652	\$5,455
panitumumab	Vectibix	2006	\$7,991	\$9,370
sunitinib maleate	Sutent	2006	\$4,590	\$5,382
thalidomide	Thalomid, Synovir	2006	\$5,613	\$6,581
vorinostat	Zolinza	2006	\$8,134	\$9,537
ixabepilone	Ixempra	2007	\$6,781	\$7,731
lapatinib ditosylate	Tykerb	2007	\$3,124	\$3,562
nilotinib	Tasigna	2007	\$6,140	\$7,000
temsirolimus	Torisel	2007	\$5,497	\$6,267
degarelix	Firmagon	2008	\$595	\$653
bendamustine HCL	Treanda	2008	\$7,026	\$7,714
everolimus	Afinitor	2009	\$7,885	\$8,688
pralatrexate injection	Folotyn	2009	\$19,732	\$21,741
pazopanib	Votrient	2009	\$6,013	\$6,625
romidepsin	Istodax	2009	\$16,958	\$18,685
ofatumumab	Arzerra	2009	\$18,315	\$19,854
cabazitaxel	Jevtana Injection	2010	\$10,842	\$11,754
sipuleucel-T	Provenge	2010	\$35,588	\$38,580
eribulin mesylate	Halaven	2010	\$6,193	\$6,714
ipilimumab	Yervoy	2011	\$37,956	\$39,888
vandetanib	Caprelsa	2011	\$10,413	\$10,943
abiraterone acetate	Zytiga	2011	\$5,259	\$5,527
vemurafenib tablets	Zelboraf	2011	\$10,767	\$11,315
brentuximab vedotin	Adcetris	2011	\$19,495	\$20,487
crizotinib	Xalkori	2011	\$11,011	\$11,571
asparaginase Erwinia chrysanthemi	Erwinaze	2011	\$24,622	\$24,984
ruxolitinib phosphate	Jakafi	2011	\$8,865	\$8,865
axitinib	Inlyta	2012	\$9,291	\$9,566
vismodegib	Erivedge	2012	\$8,546	\$8,799
ziv-aflibercept	Zaltrap	2012	\$11,063	\$11,390
enzalutamide	Xtandi	2012	\$7,078	\$7,287
bosutinib	Bosulif	2012	\$8,287	\$8,532
regorafenib	Stivarga	2012	\$9,620	\$9,905
omacetaxine mepesuccinate	Synribo	2012	\$6,357	\$6,545
cabozantinib	Cometriq	2012	\$9,921	\$10,214
ponatinib	Iclusig	2012	\$9,104	\$9,373
carfilzomib	Kyprolis	2012	\$7,959	\$8,077
pertuzumab	Perjeta	2012	\$7,758	\$7,872
ado-trastuzumab emtansine	Kadcyla	2013	\$10,635	\$10,791
pomalidomide	Pomalyst	2013	\$11,336	\$11,502
trametinib	Mekinist	2013	\$8,812	\$8,942
dabrafenib	Tafinlar	2013	\$9,411	\$9,549
Ra 223	Xofigo	2013	\$12,455	\$12,638
ibrutinib	Imbruvica	2013	\$10,900	\$11,060

obinutuzumab	Gazyva	2013	\$5,878	\$5,964
afatanib	Gilotrif	2013	\$6,071	\$6,071
ceritinib	Zykadia	2014	\$13,672	\$13,672
ramucirumab	Cyramza	2014	\$13,256	\$13,256
pembrolizumab	Keytruda	2014	\$8,725	\$8,725
blinatumomab	Blincyto	2014	\$64,260	\$64,260